Related Experiment Video
Updated: Dec 3, 2025

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
Published on: June 11, 2011
COVID-19 in people living with HIV: A multicenter case-series study
Alfonso Cabello1, Belén Zamarro1, Sara Nistal2
1Division of Infectious Diseases, Fundación Jiménez Díaz University Hospital, Research Health Institute, Autónoma de Madrid University (IIS-FJD, UAM), Spain.
Insights
COVID-19 outcomes in people living with HIV (PLHIV) are primarily determined by age and comorbidities, not HIV severity or antiretroviral therapy. PLHIV experienced similar hospitalization and ICU admission rates but lower mortality compared to those without HIV.
Area of Science:
- Infectious Diseases
- Virology
- Public Health
Background:
- Limited data exists on the impact of COVID-19 on individuals living with HIV (PLHIV).
- Understanding COVID-19's effects on PLHIV is crucial for public health strategies and clinical management.
Purpose of the Study:
- To investigate the clinical presentation, severity, and outcomes of COVID-19 in people living with HIV.
- To compare COVID-19 outcomes between PLHIV and individuals without HIV.
Main Methods:
- An observational study was conducted in four Madrid hospitals.
- Included were HIV patients with confirmed or suspected COVID-19, compared to non-HIV COVID-19 patients.
- Data collected included demographics, comorbidities, symptoms, disease severity, hospitalization, ICU admission, and mortality.
Main Results:
- Sixty-three PLHIV with COVID-19 were analyzed; 84.1% had comorbidities. Common symptoms included fever, cough, and dyspnea.
- Pneumonia occurred in 47.5%, severe disease in 28.6%, and hospitalization in 32.3%. ICU admission and mortality rates were 3.17%.
- Age, hypertension, overweight, and diabetes were associated with COVID-19 severity. HIV-related factors did not influence outcomes. Hospitalization and ICU rates were similar to non-HIV patients, with lower mortality in PLHIV.
Conclusions:
- Established COVID-19 prognostic factors like age and comorbidities are key determinants for PLHIV.
- HIV severity and antiretroviral therapy type did not appear to affect COVID-19 outcomes.
- Further large prospective studies are needed to fully elucidate differences between HIV-positive and HIV-negative patients.
Objectives:
Information on how COVID-19 affects people living with HIV (PLHIV) remains scarce.
Methods:
An observational study was conducted in four public hospitals in Madrid. All HIV patients with confirmed or suspected COVID-19 were included and compared with COVID-19 patients without HIV infection.
Results:
Sixty-three patients with HIV infection and confirmed or suspected COVID-19 were analyzed. The median age was 46 years (IQR: 37-56 years), and 88.9% were men. The median duration of HIV infection was 10.8 years (IQR: 6.5-16.8 years), and 96.8% were on antiretroviral therapy. 84.1% had previous comorbidities. The most common symptoms were fever (66.1%), cough (66.1%) and dyspnea (46.8%). Pneumonia was found in 47.5%, 28.6% of patients had severe disease, and 32.3% were admitted to hospital. The ICU admission rate and the mortality rate were both 3.17%. A significant association was observed between age, arterial hypertension, overweight, and diabetes mellitus and the severity of COVID-19. No association was observed between HIV-related factors and the severity of COVID-19. The rate of COVID-19 in HIV-patients was 1.68%. Similar hospitalization (31.74% vs 32.57%) and ICU admission (3.17% vs 2%) rates were observed with non-HIV infected patients. A lower mortality rate during hospitalization (10% vs 21.37%) and a lower global mortality rate (3.17% vs 6.96%) were also observed.
Conclusions:
Established poor prognostic factors for COVID-19 patients, such as age and comorbidities, remain the main determinants for PLHIV. Neither the HIV severity nor the type of ARV treatment seem to influence the outcome of COVID-19. Large prospective cohorts are needed in order to establish the differences between HIV-positive and HIV-negative patients.
More Related Videos
09:54Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
Published on: December 3, 2019
13:58Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
Related Concept Videos
Sexually Transmitted Infections
Retrovirus Life Cycles
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Bioavailability Study Design: Healthy Subjects Versus Patients
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...